GLUCOTRACK ANNOUNCES POSTER PRESENTATION ON CONTINUOUS BLOOD GLUCOSE MONITOR SURVEY DATA AT THE ASSOCIATION OF DIABETES CARE AND EDUCATION SPECIALISTS (ADCES) 2024 ANNUAL CONFERENCE
Glucotrack Inc. (Nasdaq: GCTK) announced a poster presentation at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference in New Orleans, LA, from August 9-12, 2024. The poster, titled 'Evaluating Acceptance of a Continuous Blood Glucose Monitor for Insulin-Requiring People with Diabetes', will showcase market research data on the acceptance of Glucotrack's Continuous Blood Glucose Monitor (CBGM) concept among people with type 1 and type 2 diabetes.
CEO Paul V. Goode emphasized the growing interest in expanding glucose monitoring options. The poster session is scheduled for Saturday, August 10, from 12:15 PM to 1:15 PM Eastern time. Glucotrack will make the poster available on their website following the conference presentation.
Glucotrack Inc. (Nasdaq: GCTK) ha annunciato una presentazione di poster presso la Conferenza Annuale dell'Associazione dei Specialisti nella Cura e Educazione del Diabete (ADCES) 2024 a New Orleans, LA, dal 9 al 12 agosto 2024. Il poster, dal titolo 'Valutazione dell'Accettazione di un Monitor Continuuo della Glucosio nel Sangue per Persone con Diabete che Richiedono Insulina', presenterà dati di ricerca di mercato sull'accettazione del concetto di Monitor Continua della Glucosio nel Sangue (CBGM) di Glucotrack tra le persone con diabete di tipo 1 e tipo 2.
Il CEO Paul V. Goode ha sottolineato il crescente interesse per l'espansione delle opzioni di monitoraggio della glucosio. La sessione del poster è programmata per sabato 10 agosto, dalle 12:15 PM alle 1:15 PM ora orientale. Glucotrack renderà disponibile il poster sul proprio sito web dopo la presentazione della conferenza.
Glucotrack Inc. (Nasdaq: GCTK) anunció una presentación de póster en la Conferencia Anual de la Asociación de Especialistas en Cuidado y Educación de la Diabetes (ADCES) 2024 en Nueva Orleans, LA, del 9 al 12 de agosto de 2024. El póster, titulado 'Evaluando la Aceptación de un Monitor Continuo de Glucosa en Sangre para Personas con Diabetes que Requieren Insulina', mostrará datos de investigación de mercado sobre la aceptación del concepto de Monitor Continuo de Glucosa en Sangre (CBGM) de Glucotrack entre personas con diabetes tipo 1 y tipo 2.
El CEO Paul V. Goode enfatizó el creciente interés en expandir las opciones de monitoreo de glucosa. La sesión del póster está programada para el sábado 10 de agosto, de 12:15 PM a 1:15 PM hora del este. Glucotrack pondrá el póster a disposición en su sitio web después de la presentación de la conferencia.
글루코트랙 Inc. (Nasdaq: GCTK)는 2024년 연례 당뇨병 관리 및 교육 전문가 협회(ADCES) 컨퍼런스에서 포스터 발표를 진행한다고 발표했습니다. 이 행사는 2024년 8월 9일부터 12일까지 미국 뉴올리언스에서 열립니다. 포스터 제목은 '인슐린이 필요한 당뇨병 환자를 위한 지속적인 혈당 모니터의 수용성 평가'이며, 제1형 및 제2형 당뇨병 환자들 사이에서 글루코트랙의 지속적인 혈당 모니터(CBGM) 개념의 수용에 대한 시장 조사 데이터를 보여줄 것입니다.
CEO인 폴 V. 굿은 혈당 모니터링 옵션의 확대에 대한 관심이 높아지고 있음을 강조했습니다. 포스터 세션은 8월 10일 토요일, 동부 표준시 기준으로 오후 12시 15분부터 1시 15분까지 예정되어 있습니다. 글루코트랙은 회의 발표 후 웹사이트에 포스터를 게시할 것입니다.
Glucotrack Inc. (Nasdaq: GCTK) a annoncé une présentation de poster lors de la Conférence Annuelle de l'Association des Spécialistes en Soins et Éducation du Diabète (ADCES) 2024 à La Nouvelle-Orléans, LA, du 9 au 12 août 2024. Le poster, intitulé 'Évaluation de l'Acceptation d'un Moniteur Continu de Glucose Sanguin pour les Personnes Diabétiques Nécessitant de l'Insuline', mettra en avant des données de recherche de marché sur l'acceptation du concept de Moniteur Continu de Glucose Sanguin (CBGM) de Glucotrack parmi les personnes atteintes de diabète de type 1 et de type 2.
Le PDG Paul V. Goode a souligné l'intérêt croissant pour l'expansion des options de surveillance du glucose. La session du poster est prévue pour le samedi 10 août, de 12h15 à 13h15, heure de l'Est. Glucotrack mettra le poster à disposition sur son site Web après la présentation de la conférence.
Glucotrack Inc. (Nasdaq: GCTK) gab eine Posterpräsentation auf der Jahrestagung der Diabetes Care and Education Specialists (ADCES) 2024 in New Orleans, LA, bekannt, die vom 9. bis 12. August 2024 stattfindet. Das Poster mit dem Titel 'Bewertung der Akzeptanz eines kontinuierlichen Blutzuckermonitors für insulinpflichtige Diabetespatienten' wird Marktforschungsdaten zur Akzeptanz des Konzeptes des kontinuierlichen Blutzuckermonitors (CBGM) von Glucotrack bei Menschen mit Typ-1- und Typ-2-Diabetes präsentieren.
CEO Paul V. Goode betonte das wachsende Interesse an der Erweiterung der Möglichkeiten zur Blutzuckerüberwachung. Die Postersitzung ist für Samstag, den 10. August, von 12:15 Uhr bis 13:15 Uhr Ostküstenzeit geplant. Glucotrack wird das Poster nach der Konferenzpräsentation auf seiner Website verfügbar machen.
- None.
- None.
Market research data shows interest in additional glucose monitoring options for people with diabetes who use insulin
Rutherford, NJ, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that an emerging science industry poster will be presented at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference to be held August 9-12, 2024 in New Orleans, LA.
The Glucotrack poster will present market research data on the acceptance of the Company’s Continuous Blood Glucose Monitor (CBGM) concept among people with type 1 and type 2 diabetes.
“We look forward to sharing our findings on our continuous blood glucose monitor with the diabetes care community at ADCES,” said Paul V. Goode, PhD, CEO of Glucotrack. “This data contributes to the growing body of evidence demonstrating the need for and growing interest in expanding glucose monitoring options.”
The poster will be made available on the Glucotrack website following the poster session at the conference. Presentation details are as follows; times noted are Eastern time:
Poster Title: Evaluating Acceptance of a Continuous Blood Glucose Monitor for Insulin-Requiring People with Diabetes
Poster Session Date / Time: Saturday, August 10, 12:15 PM - 1:15 PM
For more information about Glucotrack’s CBGM, visit glucotrack.com.
# # #
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 2+ years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 28, 2024.
Contacts:
Investor Relations:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
FAQ
What is Glucotrack (GCTK) presenting at the ADCES 2024 Annual Conference?
When and where is the ADCES 2024 Annual Conference where Glucotrack (GCTK) is presenting?
What does the Glucotrack (GCTK) poster presentation at ADCES 2024 focus on?
How can I access Glucotrack's (GCTK) poster presentation from the ADCES 2024 conference?
